The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 304, Issue 12, 2013, Pages

  Plamboeck, Astrid ^a,b   Veedfald, Simon ^a   Deacon, Carolyn F ^b   Hartmann, Bolette ^b   Wettergren, André ^a   Svendsen, Lars B ^a   Meisner, Søren ^a   Hovendal, Claus ^c   Vilsbøll, Tina ^a   Knop, Filip K ^a,b   Holst, Jens J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b University of Copenhagen   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Degradation; DPP 4; GLP 1; Insulin and glucagon secretion; Meal test; Vagotomy; Vagus nerve

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN;

AGED; APPETITE; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FOOD INTAKE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HUMAN; INNERVATION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NAUSEA; PALATABILITY; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PYLOROPLASTY; SATIETY; SHAM FEEDING; STOMACH EMPTYING; SYSTOLIC BLOOD PRESSURE; TEST MEAL; THIRST; TRUNCUS VAGOTOMY; VAGUS NERVE; VAGUS NERVE STIMULATION; VISUAL ANALOG SCALE; WAIST HIP RATIO; WELLBEING;

DEGRADATION; DPP-4; GLP-1; INSULIN AND GLUCAGON SECRETION; MEAL TEST; VAGOTOMY; VAGUS NERVE;

AGED; DUODENAL ULCER; EATING; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; MALE; MEALS; PYLORUS; VAGOTOMY;

EID: 84879189059     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00035.2013     Document Type: Article

References (72)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JRC, Ghatei MA, Bloom SR. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131, 2005.
2. Ahrén B. Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol 286: R269-R272, 2004.
3. Asmar M, Bache M, Knop FK, Madsbad S, Holst JJ. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab 95: 2367-2375, 2010.
4. Balaji NS, Crookes PF, Banki F, Hagen JA, Ardill JE, DeMeester TR. A safe and noninvasive test for vagal integrity revisited. Arch Surg 137: 954-958; discussion 958-959, 2002.
5. Balkan B, Li X. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454, 2000.
6. Blat S, Guérin S, Chauvin A, Sève B, Morgan L, Cuber JC, Malbert CH. The vagus is inhibitory of the late postprandial insulin secretion in conscious pigs. Auton Neurosci 101: 68-77, 2002.
7. Boyle PJ, Liggett SB, Shah SD, Cryer PE. Direct muscarinic cholinergic inhibition of hepatic glucose production in humans. J Clin Invest 82: 445-449, 1988.
8. Bucinskaite V, Tolessa T, Pedersen J, Rydqvist B, Zerihun L, Holst JJ, Hellström PM. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 21: 978-e78, 2009.
9. Corssmit EP, Van Lanschot JJ, Romijn JA, Endert E, Sauerwein HP. Truncal vagotomy does not affect postabsorptive glucose metabolism in humans. J Appl Physiol 79: 97-101, 1995.
10. Deacon CF, Johnsen AH, Holst JJ. Human colon produces fully processed glucagon-like peptide-1 (7-36) amide. FEBS Lett 372: 269-272, 1995.
11. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab 271: E458-E464, 1996.
12. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172: 355-362, 2002.
13. Deane AM, Nguyen NQ, Stevens JE, Fraser RJL, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK, Horowitz M. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95: 215-221, 2010.
14. Delgado-Aros S, Vella A, Camilleri M, Low PA, Burton DD, Thomforde GM, Stephens D. Effects of glucagon-like peptide-1 and feeding on gastric volumes in diabetes mellitus with cardio-vagal dysfunction. Neurogastroenterol Motil 15: 435-443, 2003.
15. Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, Jacobsen SH, Clausen TR, Worm D, Hartmann B, Rehfeld JF, Damgaard M, Madsen JL, Madsbad S, Holst JJ, Hansen DL. Gut hormones, early dumping and resting energy expenditure in patients with good and poor weight loss response after Roux-en-Y gastric bypass. Int J Obes (Lond) (February 19, 2013). doi: 10.1038/ijo.2013.15.
16. Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626-630, 1995.
17. Dupré J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 89: 3469-3473, 2004.
18. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucoseinduced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 92: 4165-4171, 2007.
19. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520, 1998.
20. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 24: 38-48, 2000.
21. Flint A, Raben A, Ersbøll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 25: 781-792, 2001.
22. Gregersen NT, Møller BK, Raben A, Kristensen ST, Holm L, Flint A, Astrup A. Determinants of appetite ratings: the role of age, gender, BMI, physical activity, smoking habits, and diet/weight concern. Food Nutr Res 55, 2011. doi: 10.3402/fnr.v55i0.7028. Epub 2011 Aug 11.
23. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch 435: 583-594, 1998.
24. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 276: R1541-R1544, 1999.
25. Gutzwiller JP, Drewe J, Göke B, Schmidt H, Rohrer B, Lareida J, Beglinger C. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol Regul Integr Comp Physiol 276: R1541-R1544, 1999.
26. Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44: 81-86, 1999.
27. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363, 1999.
28. Hansen L, Lampert S, Mineo H, Holst JJ. Neural regulation of glucagon-like peptide-1 secretion in pigs. Am J Physiol Endocrinol Metab 287: E939-E947, 2004.
29. Henderson JR, Jefferys DB, Jones RH, Stanley D. The effect of atropine on the insulin release caused by oral and intravenous glucose in human subjects. Acta Endocrinol 83: 772-780, 1976.
30. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439, 2007.
31. Holst. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10: 229-235, 1999.
32. Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv Ther 30: 81-101, 2013.
33. Humphrey CS, Dykes JR, Johnston D. Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part II-Comparison of response to oral and intravenous glucose. Br Med J 2: 114-116, 1975.
34. Humphrey CS, Dykes JR, Johnston D. Effects of truncal, selective, and highly selective vagotomy on glucose tolerance and insulin secretion in patients with duodenal ulcer. Part I-Effect of vagotomy on response to oral glucose. Br Med J 2: 112-114, 1975.
35. Imeryüz N, Yeǧen BC, Bozkurt A, Cokun T, Villanueva-Peñacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol Gastrointest Liver Physiol 273: G920-G927, 1997.
36. Jorgensen NB, Jacobsen SH, Dirksen C, Bojsen-Moller KN, Naver L, Hvolris L, Clausen TR, Wulff BS, Worm D, Hansen DL, Madsbad S, Holst JJ. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab 303: (1) E122-E131, 2012.
37. Kronborg O, Madsen P. Gastric emptying rate and acid secretion after truncal vagotomy and pyloroplasty for duodenal ulceration. Scand J Gastroenterol 7: 515-518, 1972.
38. Ma J, Pilichiewicz AN, Feinle-Bisset C, Wishart JM, Jones KL, Horowitz M, Rayner CK. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 29: 604-608, 2012.
39. Medhus AW, Lofthus CM, Bredesen J, Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil 13: 179-185, 2001.
40. Meier JJ, Kemmeries G, Holst JJ, Nauck MA. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54: 2212-2218, 2005.
41. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835, 1993.
42. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261-280, 1999.
43. Miceli JN, Aravind MK, Cohen SN, Done AK. Simultaneous measurements of acetaminophen and salicylate in plasma by liquid chromatography. Clin Chem 25: 1002-1004, 1979.
44. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, Nakayama K, Uchida K. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43, 2004.
45. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60: 1561-1565, 2011.
46. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993.
47. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988, 1997.
48. Nishizawa M, Nakabayashi H, Uchida K, Nakagawa A, Niijima A. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154, 1996.
49. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, Hellström PM. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23: 304-311, 1999.
50. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013, 1988.
51. Orskov C, Poulsen SS, Møller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835, 1996.
52. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
53. Parr NJ, Grime S, Critchley M, Baxter JN, Mackie CR. Mechanisms governing the biphasic pattern of gastric emptying after truncal vagotomy and pyloroplasty. Gut 29: 1253-1257, 1988.
54. Pennathur A, Awais O, Luketich JD. Technique of minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg 89: S2159-S2162, 2010.
55. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48: 1882-1890, 2005.
56. Ponzani P. Long-term effectiveness and safety of liraglutide in clinical practice. Minerva Endocrinol 38: 103-112, 2013.
57. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulintropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725, 1995.
58. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 140: 1687-1694, 1999.
59. Rüttimann EB, Arnold M, Hillebrand JJ, Geary N, Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 150: 1174-1181, 2009.
60. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Göke B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55: 243-251, 2006.
61. Schwartz TW, Holst JJ, Fahrenkrug J, Jensen SL, Nielsen OV, Rehfeld JF, De Muckadell OB, Stadil F. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 61: 781-789, 1978.
62. Schwartz TW, Rehfeld JF, Stadil F, Larson LI, Chance RE, Moon N. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet 1: 1102-1105, 1976.
63. Schwartz TW, Stenquist B, Olbe L. Cephalic phase of pancreatic-polypeptide secretion studied by sham feeding in man. Scand J Gastroenterol 14: 313-320, 1979.
64. Sloth B, Due A, Larsen TM, Holst JJ, Heding A, Astrup A. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Br J Nutr 101: 1846-1858, 2009.
65. Talsania T, Anini Y, Siu S, Drucker DJ, Brubaker PL. Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748-3756, 2005.
66. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41: 1180-1186, 1998.
67. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, Ellis KS, Woods SC, Seeley RJ, Herman JP, D'Alessio DA. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973, 2007.
68. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342, 1989.
69. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673, 1993.
70. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol Gastrointest Liver Physiol 275: G984-G992, 1998.
71. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 46: 2256-2262, 2001.
72. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830, 2002.